Drug interactions and pharmacokinetics

Drug interactions and pharmacokinetics features

• 

  One in five Kenyan patients suffers major interactions between HIV drugs and other medicines

  ...

  From:HIV & AIDS treatment in practice

Drug interactions and pharmacokinetics news from aidsmap

• Can speeding up nevirapine clearance reduce the risk of resistance after PMTCT use?

  In a bid to reduce the risk of nevirapine resistance after the use of single-dose nevirapine to prevent mother-to-child HIV transmission, several research groups are now experimenting with the use of drugs that can speed up the clearance of nevirapine ...

  20 January 2012 | Carole Leach-Lemens

• Guidelines published on management of interactions between anti-epileptic and anti-HIV drugs

  Doses adjustments are required when certain antiretrovirals and anti-epileptic drugs are taken together, according to guidelines published in Neurology.  The guidelines were developed by a team of investigators who reviewed all the published studies reporting on interactions between anti-HIV and ...

  09 January 2012 | Michael Carter

• Efavirenz may be under-dosed in children

  In a cohort of three to 12 year-old HIV-infected Ugandan children taking once-daily efavirenz according to 2006 World Health Organization (WHO) weight-band dosing recommendations, lower and highly variable amounts of drug entered their bloodstream compared to adults, investigators from the AntiRetroviral ...

  05 October 2011 | Carole Leach-Lemens

• Crushing Kaletra tablets for kids leads to lower drug levels

  Using crushed lopinavir/ritonavir (Kaletra) tablets in children with HIV because of difficulties in swallowing whole tablets should be avoided, American researchers report in the advance online edition of the Journal of Acquired Immune Deficiency Syndromes. Brookie M Best and colleagues undertook a randomised, ...

  23 September 2011 | Carole Leach-Lemens

• Older anti-epileptic drugs associated with failure of HIV treatment

  An interaction means that some older anti-epileptic drugs and antiretroviral therapy should not be used together, a US study published in the open-access journal AIDS Research and Therapy shows. Both types of therapy are metabolised by the body using ...

  02 September 2011 | Michael Carter

• Telaprevir works well for people with HIV/HCV co-infection

  The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to interim data presented on Wednesday at the 18th Conference on Retroviruses and ...

  02 March 2011 | Liz Highleyman

• Atazanavir dose adjustment in pregnancy approved by US FDA

  The US Food and Drug Administration has approved new product labelling stating that atazanavir (Reyataz) should only be used with a booster dose of ritonavir in pregnant women. Furthermore, women who are treatment-experienced, or taking tenofovir alongside atazanavir, should receive ...

  07 February 2011 | Keith Alcorn

• Atazanavir levels reduced during pregnancy, especially when used with tenofovir

  Blood levels of the protease inhibitor atazanavir (Reyataz) are reduced during pregnancy, research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes shows. Atazanavir levels were even lower when pregnant women took the drug ...

  02 February 2011 | Michael Carter

• High bilirubin levels may be more frequent in adolescents taking atazanavir

  High bilirubin levels may be more frequent in adolescents taking the protease inhibitor atazanavir (Reyataz) than in adults, Spanish investigators warn in the Journal of Adolescent Health. Elevated bilirubin can lead to the development of a side-effect called hyperbilirubinaemia, which involves a ...

  01 February 2011 | Michael Carter

• Nevirapine / rifampicin interaction linked to higher recurrence of TB in people on ART

  People with HIV and tuberculosis who took a once-daily nevirapine regimen alongside TB treatment containing rifampicin were significantly more likely to develop a recurrence of TB than people taking efavirenz (Sustiva or Stocrin, also in the combination pill Atripla) ...

  16 November 2010 | Keith Alcorn

More news

Drug interactions and pharmacokinetics news selected from other sources

• Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

  The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6. 

  08 February 2012 | AIDSMeds

• Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels

  HIV/HCV coinfected people who take the HCV protease inhibitor boceprevir (Victrelis) for hepatitis C treatment along with a ritonavir-boosted HIV protease inhibitor may experience drug-drug interactions that reduce concentrations of both drugs to ineffective levels, Merck warned this week.

  07 February 2012 | HIVandHepatitis.com

• Guidelines stress caution when combining anti-epileptic, HIV drugs

  New guidelines will help physicians better choose seizure drugs for people on HIV/AIDS medication, avoiding deadly drug interactions and preventing critical anti-HIV drugs from becoming less effective, possibly leading to a more virulent strain of the disease.

  04 January 2012 | Science Daily

• Guidelines stress caution when combining anti-epileptic, HIV drugs

  New guidelines from the American Academy of Neurology will help physicians better choose seizure drugs for people on HIV/AIDS medication, avoiding deadly drug interactions and preventing critical anti-HIV drugs from becoming less effective, possibly leading to a more virulent strain of the disease.

  04 January 2012 | Medical Xpress

• BMS to develop Reyataz fixed-dose pill with Gilead booster drug

  Bristol-Myers Squibb and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor Reyataz (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

  26 October 2011 | MarketWatch

• Innovative transdermal patch for delivery of HIV medicine

  An innovative delivery method for human immunodeficiency virus medications has been developed through use of a transdermal patch, the first of its kind to treat HIV.

  25 October 2011 | Science Daily

• ICAAC: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

  The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.

  06 October 2011 | HIVandhepatitis.com

• Varying efficacy of HIV drug cocktails explained

  A new mathematical model of HIV-fighting drugs reveals the biology beneath the varying success of such treatments. 

  13 July 2011 | Science News

• HIV disrupts blood-brain barrier: Cellular study suggests way virus may cause neurological deficits

  HIV weakens the blood-brain barrier by overtaking a small group of supporting brain cells, according to a new study. The findings may help explain why some people living with HIV experience neurological complications, despite the benefits of modern drug regimens.

  28 June 2011 | Science Daily

• Certain Anti-Seizure Drugs Up the Risk of HIV Treatment Failure

  People taking older anti-seizure medications that are broken down by the same liver enzyme (CYP3A4) as many common antiretroviral (ARV) drugs were more likely to experience treatment failure than people taking seizure medications that aren’t broken down by that liver enzyme.

  14 June 2011 | AIDSMeds

More news